Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-18
2006-04-18
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S235000, C544S116000, C514S248000
Reexamination Certificate
active
07030112
ABSTRACT:
Disclosed are pyrrolopyridazine compounds of the formula,wherein the substituents are defined herein,methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
REFERENCES:
patent: 6472389 (2002-10-01), Ohtani et al.
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/56738 (2000-09-01), None
Letsinger et al. {J. Org. Chem. (1956), 21, 764-6}.
Flitsch et al. {Tetrahedron Letters (1968), (12), 1479-84}.
Boyce, B.F. et al., “Requirement of pp60c-SrcExpression for Osteoclasts to Form Ruffled Borders and Resorb Bone in Mice”, J. Clin. Invest., vol. 90, pp. 1622-1627 (1992).
Campbell, S.L. et al., “Increasing complexity of Ras signaling”, Oncogene, vol. 17, pp. 1395-1413 (1998).
Du, et al., “Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD”, American Journal of Physiology, vol. 269, No. 2, Part 1, pp. C487-C495 (1995).
Dudley, D.T. et al., “A synthetic inhibitor of the mitogen-activated protein kinase cascade”, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7686-7689 (1995).
Ellis, L.M. et al., “Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific forc-src”, The Journal of Biological Chemistry, vol. 273, No. 2, pp. 1052-1057 (1998).
Gattone II, V.H. et al., “Epidermal Growth Factor Ameliorates Autosomal Recessive Polycystic Kidney Disease in Mice”, Developmental Biology, vol. 169, pp. 504-510 (1995).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Missbach, M. et al., “A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models in Vivo”, Bone, vol. 24, No. 5, pp. 437-449 (1999).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis”, Ann. of Intern. Med., vol. 130, pp. 478-486 (1999).
Nauta, J. et al., “Biliary Epithelial Cells from Mice with Congenital Polycystic Kidney Disease Are Hyperresponsive to Epidermal Growth Factor”, Pediatric Research, vol. 37, No. 6, pp. 755-763 (1995).
Nistér, M. et al., “Differential Expression of Platelet-derived Growth Factor Receptors in Human Malignant Glioma Cell Lines”, The Journal of Biological Chemistry, vol. 266, No. 25, pp. 16755-16763 (1991).
O'Reilly, M.S. et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma”, Cell, vol. 79, pp. 315-328 (1994).
O'Reilly, M.S. et al., “Angiostatin induces and sustains dormancy of human primary tumors in mice”, Nature Medicine, vol. 2, No. 6, pp. 689-692 (1996).
O'Reilly, M.S. et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth”, Cell, vol. 88, pp. 277-285 (1997).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medical Chemistry, vol. 6, pp. 807-823 (1999).
Sato, T.N. et al., “Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation”, Nature, vol. 376, pp. 70-74 (1995).
Schwartzberg, P.L., “The many faces of Src: multiple functions of a prototypical tyrosine kinase”, Oncogene, vol. 17, pp. 1463-1468 (1998).
Seger, R. et al., “The MAPK signaling cascade”, FASEB J., vol. 9, pp. 726-735 (1995).
Sivaraman, V.S. et al., “Hyperexpression of Mitogen-activated Protein Kinase in Human Breast Cancer”, J. Clin. Invest., vol. 99, No. 7, pp. 1478-1483 (1997).
Soriano, P. et al., “Targeted Disruption of thec-srcProto-Oncogene Leads to Osteopetrosis in Mice”, Cell, vol. 64, pp. 693-702 (1991).
Staley, C.A. et al., “Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific forc-Src”, Cell Growth and Differentiation, vol. 8, pp. 269-274 (1997).
Strawn, L.M. et al., “Inhibition of Glioma Cell Growth by a Truncated Platelet-derived Growth Factor-β Receptor”, The Journal of Biological Chemistry, vol. 269, No. 33, pp. 21215-21222 (1994).
Wilson, P.D. et al., “Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease”, European Journal of Cell Biology, vol. 61, pp. 131-138 (1993).
Chen Jinsheng
Illig Carl R.
Meegalla Sanath K.
Salvati Mark E.
Wall Mark James
Berch Mark L.
Bristol--Myers Squibb Company
Habte Kahsay
Korsen Elliott
LandOfFree
Pyrrolopyridazine compounds and methods of use thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolopyridazine compounds and methods of use thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolopyridazine compounds and methods of use thereof for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567142